BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $11.49B
• Dividend Yield: N/A
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): 21.7
• Beta (1Y): 0.43
• Revenue Growth: 17.99%
• EPS Growth: 152.10%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): 0.95
• Shares Outstanding: 191,775,670
• 10 Day Avg. Volume: 2,175,947
• 30 Day Avg. Volume: 1,916,226
• PEG Ratio: 0.97
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.20
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 0.97
• Enterprise Value/Gross Profit: 4.68
• Enterprise Value/Ebitda: 4.67
• 1Y Price Target: $97.40
• Price Target Upside: 67.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 71 Outperform
• Price Target: $67.00 ▲( 15.50% Upside)

BioMarin Pharmaceutical is positioned strongly due to its robust financial performance and strategic acquisition, which enhances its growth potential. However, bearish technical indicators suggest caution in the short term. The company is reasonably valued given its growth prospects, with positive sentiment from the earnings call underscoring its strategic positioning and operational strength. The outlook remains optimistic, though investors should be mindful of technical trends and potential risks related to VOXZOGO's revenue dynamics and tariff exposure.

Positive Factors

Acquisition Strategy

The acquisition of Inozyme Pharma is seen as a step in the right direction for BioMarin's pipeline expansion.

Financial Performance

BioMarin's management reiterated the company's goal of achieving a 40% non-GAAP operating margin in 2026, indicating confidence in future performance.

Revenue Potential

Management anticipates the potential for significant peak revenues from INZ-701, which could add considerable upside to BioMarin's sales estimates.

Negative Factors

Time to Revenue

There is sizable revenue potential, but it may take some time to fully materialize.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin Pharmaceutical generates revenue through the development, production, and sales of its pharmaceutical products. The company's primary revenue streams come from the commercial sales of its approved therapies, such as Kuvan and Palynziq for PKU and Vimizim for MPS IV. BioMarin also earns money through collaborations and licensing agreements with other pharmaceutical companies, leveraging its proprietary research and development capabilities. Additionally, the company may receive milestone payments and royalties from partnered products. Key factors contributing to its earnings include successful product launches, regulatory approvals, and the expansion of its product pipeline addressing rare and underserved medical conditions.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates strong financial performance with significant revenue and profit growth. The company's income statement shows robust revenue growth from $2.09 billion in 2022 to $2.93 billion TTM, with improved profit margins. The balance sheet is solid with low leverage, and cash flow management is commendable with strong free cash flow growth. These factors enhance the company's financial stability and operational efficiency.

Income Statement

BioMarin Pharmaceutical has demonstrated a robust financial performance with strong revenue growth, rising from $2.09 billion in 2022 to $2.93 billion TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, supported by efficient cost management. The net profit margin and EBIT margins have also shown significant improvement, indicating enhanced profitability. The consistent EBITDA margin growth highlights operational efficiency gains.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio, suggesting prudent financial leverage. The equity ratio is impressive, indicating a high level of asset financing through equity. The return on equity has improved substantially, showcasing the company's ability to generate profits from shareholders' investments. However, the company should continue monitoring its debt levels to maintain financial flexibility.

Cash Flow

BioMarin Pharmaceutical has demonstrated strong cash flow dynamics with significant growth in free cash flow, reflecting effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating robust cash generation capabilities. The improved free cash flow to net income ratio further underscores the company's solid cash flow management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.94B	2.85B	2.42B	2.10B	1.85B	1.86B
	Gross Profit
2.32B	2.27B	1.84B	1.61B	1.38B	1.34B
	EBIT
602.65M	484.21M	194.44M	57.55M	-60.01M	-96.26M
	EBITDA
738.30M	650.86M	310.28M	267.51M	48.03M	-5.85M
	Net Income Common Stockholders
523.88M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.05B	1.14B	1.07B	1.29B	1.01B	1.07B
	Total Assets
6.87B	6.99B	6.84B	6.38B	6.00B	5.85B
	Total Debt
1.09B	602.71M	1.10B	1.08B	1.08B	1.08B
	Net Debt
340.97M	-340.13M	340.62M	358.49M	491.80M	425.99M
	Total Liabilities
1.80B	1.33B	1.89B	1.77B	1.73B	1.74B
	Stockholders Equity
5.07B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow		Free Cash Flow
620.18M	475.42M	51.65M	44.36M	185.31M	-52.15M
	Operating Cash Flow
700.26M	572.84M	159.26M	175.90M	304.54M	85.36M
	Investing Cash Flow
122.49M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
	Financing Cash Flow
-522.43M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 58.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Negative. The current price of 58.01 is below the 20-day moving average (MA) of 60.55, below the 50-day MA of 63.45, and below the 200-day MA of 69.13, indicating a bearish trend. The MACD of -1.18 indicates Positive momentum. The RSI at 39.57 is Neutral, neither overbought nor oversold. The STOCH value of 25.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	81 Outperform	$12.51B	11.52	22.69%	―	25.11%	46.46%
EXEL	80 Outperform	$12.10B	19.83	30.22%	―	24.49%	244.87%
UTHR	79 Outperform	$13.96B	12.36	19.94%	―	19.85%	21.16%
BMRN	71 Outperform	$11.49B	21.70	9.64%	―	17.99%	152.10%
INCY	71 Outperform	$12.64B	200.43	0.47%	―	17.13%	-88.78%
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
ASND	52 Neutral	$9.75B	―	357.68%	―	10.69%	34.71%

BioMarin Pharmaceutical Corporate Events

BioMarin Acquires Inozyme Pharma for $270 Million

On May 16, 2025, BioMarin Pharmaceutical Inc. announced an agreement to acquire Inozyme Pharma, Inc. for approximately $270 million. This acquisition aims to enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, a rare genetic condition. The transaction is expected to close in the third quarter of 2025, pending regulatory approval and other conditions. The acquisition is strategically significant for BioMarin, as it aligns with their commitment to advancing treatments for serious genetic conditions, potentially offering the first treatment for ENPP1 Deficiency. The first pivotal data readout for INZ-701 in children is anticipated in early 2026, with a potential launch in 2027, marking a significant step forward in addressing unmet medical needs.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Expands Board with New Independent Director

On February 20, 2025, BioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P. Walbert as an independent director effective February 24, 2025. Mr. Walbert will receive standard director fees and a pro rata share of the 2024 annual award of $400,000 in restricted stock units, with shares vesting before the next annual meeting of stockholders. This appointment does not result from any arrangement or related party transaction.